XML 56 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Segment Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
segment
Mar. 31, 2017
USD ($)
Medical Indication Information        
Contract manufacturing revenue $ 5,586 $ 2,178 $ 15,771 $ 15,266
Net sales 174,386 165,720 513,652 498,223
Settlement agreement   (4,000)   (4,000)
Total net sales 174,386 161,720 $ 513,652 494,223
Segment information        
Number of Reportable Segments | segment     1  
Antibiotic        
Medical Indication Information        
Net sales 3,801 4,474 $ 10,701 13,047
Anti-Psychosis        
Medical Indication Information        
Net sales 9,336 14,433 47,127 47,119
Cardiovascular        
Medical Indication Information        
Net sales 18,514 14,815 39,955 39,484
Central Nervous System        
Medical Indication Information        
Net sales 8,395 11,124 24,137 32,028
Gallstone        
Medical Indication Information        
Net sales 3,828 11,157 15,674 37,465
Gastrointestinal        
Medical Indication Information        
Net sales 16,562 19,441 46,171 56,470
Glaucoma        
Medical Indication Information        
Net sales 875 4,868 5,706 15,962
Migraine        
Medical Indication Information        
Net sales 12,888 7,043 43,387 22,066
Muscle Relaxant        
Medical Indication Information        
Net sales 3,299 3,673 10,309 10,208
Pain Management        
Medical Indication Information        
Net sales 6,594 6,085 18,483 20,132
Respiratory        
Medical Indication Information        
Net sales 2,324 4,256 6,200 9,426
Thyroid Deficiency        
Medical Indication Information        
Net sales 69,975 44,999 185,983 130,267
Urinary        
Medical Indication Information        
Net sales 33 2,619 5,870 12,413
Other        
Medical Indication Information        
Net sales $ 12,376 $ 14,555 $ 38,178 $ 36,870